Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Pooled Post Hoc Analyses Through 1 Year of Two Phase 3 Studies

被引：0
|
作者：
Coates, Laura C. [1 ]
Ramirez, Julio [2 ]
McGonagle, Dennis [3 ]
Aydin, Sibel [4 ]
Zimmermann, Miriam [5 ]
Nantel, Francois [6 ]
Shawi, May [7 ]
Rampakakis, Emmanouil [8 ,9 ]
Nash, Peter [10 ,11 ]
Mease, Philip [12 ,13 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford, England
[2] Hosp Clin Barcelona, Dept Rheumatol, Arthrit Unit, Barcelona, Spain
[3] Univ Leeds, Leeds Biomed Res Ctr, Leeds, England
[4] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[5] Janssen Sci Affairs LLC, Immunol, Zug, Switzerland
[6] Nantel Medsci Consult, Montreal, PQ, Canada
[7] Janssen Pharmaceut Co Johnson Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada
[9] JSS Med Res, Montreal, PQ, Canada
[10] Griffith Univ, Maroochydore, Australia
[11] Univ Queensland, Maroochydore, Australia
[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[13] Univ Washington, Seattle, WA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB152 / AB152
页数：1
相关论文
共 50 条
  • [41] HERPES ZOSTER IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED ANALYSES OF TOFACITINIB PHASE 2, 3 AND LONG-TERM EXTENSION STUDIES IN A LATIN AMERICAN SUBPOPULATION
    Zerbini, Cristiano A. F.
    Radominski, Sergio C.
    Cardiel, Mario
    Castaneda, Oswaldo
    Citera, Gustavo
    Neira, Oscar
    Ponce de Leon, Dario
    Hoffman, Elaine
    Rojo, Ricardo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 124 - 124
  • [42] Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
    Merola, Joseph
    Callis-Duffin, Kristina
    Padilla, Byron
    Yue, Cuiyong
    Photowala, Huzefa
    Kaplan, Blair
    McInnes, Iain B.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 602 - 603
  • [43] DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICTS LONG-TERM OUTCOMES IN AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
    van der Heijde, D.
    Deodhar, A.
    Fleischmann, R.
    Rudwaleit, M.
    Davies, O.
    Nurminen, T.
    Mease, P. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 786 - 786
  • [44] LONG-TERM WORK PRODUCTIVITY IMPROVEMENT ASSOCIATED WITH APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES
    Zhang, Frank
    Clancy, Zoe
    Li, Stan
    Mughal, Farhan
    RHEUMATOLOGY, 2017, 56 : 80 - 80
  • [45] Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
    Mease, Philip
    Poddubnyy, Denis
    Bajracharya, Rajan
    Ink, Barbara
    Marten, Alexander
    Massow, Ute
    Shende, Vishvesh
    Manente, Myriam
    Peterson, Luke
    White, Katy
    Nash, Peter
    Gensler, Lianne S.
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4786 - 4789
  • [46] Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies.
    Burmester, G.
    Blanco, Ricardo
    Rubbert-Roth, Andrea
    Hendrikx, Thijs
    Kwok, Kenneth
    Bradley, John
    Zwillich, Samuel H.
    Benda, Birgitta
    Mebus, Charles A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4172 - 4172
  • [47] Reduction in fatigue in patients with active psoriatic arthritis is sustained over 2 years: long-term results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Gossec, L.
    Conaghan, P.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 33 - 33
  • [48] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS ARE SUSTAINED OVER 2 YEARS: LONG-TERM RESULTS OF TWO PHASE 3 STUDIES WITH SECUKINUMAB
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 351 - 351
  • [49] Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
    Ritchlin, Christopher T.
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Schiopu, Elena
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Shawi, May
    Jiang, Yusang
    Sheng, Shihong
    Wang, Yanli
    Xu, Stephen
    Merola, Joseph F.
    McInnes, Iain B.
    Deodhar, Atul
    RMD OPEN, 2022, 8 (01):
  • [50] Secukinumab effects on cardiovascular risk factors in patients with psoriasis, psoriatic arthritis and axial spondyloarthritis: Results from post hoc analyses of pooled data from 19 phase 3/4 clinical studies
    Merola, Joseph F.
    McInnes, Iain B.
    Deodhar, Atul A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB107 - AB107
12345